Payment overview · 2025
General Payments
$869.35
50 reported records · 13 companies
Healthcare provider profile · identity verified
Michael Allen Mitchell, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HENRIETTA, TX · NPI 1770561904
Verified facts
What the public records show
CMS Open Payments records show Michael Allen Mitchell, D.O. received $869.35 in general payments during 2025 across 50 reported records.
Corcept Therapeutics accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Kerendia, Korlym, Mounjaro, Ozempic, Rybelsus.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Kerendia by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Korlym by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 398 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $252.17 | 29.0% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $138.37 | 15.9% | 9 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.06 | 15.8% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $84.87 | 9.8% | 5 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $45.79 | 5.3% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.88 | 3.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.13 | 3.8% | 2 | 2025 |
| Ceribell, Inc. | Unresolved — no canonical attribution shown | $28.74 | 3.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $22.67 | 2.6% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $17.78 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.38 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.01 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $814.60 | 48 |
| Education | $54.75 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $252.17 | 17 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $138.37 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $138.37 | 9 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $137.06 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $84.87 | 5 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $45.79 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| POCKET EEG DEVICE Normalized: pocket eeg device |
Device | Ceribell, Inc. | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 59 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 190 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 398 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
172 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
190 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
398 | 69 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 398 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 351 | 107 |
| Mounjaro | Tirzepatide | 190 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 174 | 49 |
| Jardiance | Empagliflozin | 172 | 39 |
| Allopurinol | Allopurinol | 167 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 44 |
| Gabapentin | Gabapentin | 157 | 44 |
| Potassium Chloride | Potassium Chloride | 156 | 50 |
| Lisinopril | Lisinopril | 136 | 42 |
| Metformin Hcl | Metformin Hcl | 129 | 40 |
| Tramadol Hcl | Tramadol Hcl | 128 | 31 |
| Telmisartan | Telmisartan | 125 | 35 |
| Furosemide | Furosemide | 122 | 35 |
| Montelukast Sodium | Montelukast Sodium | 101 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 28 |
| Eliquis | Apixaban | 98 | 18 |
| Ezetimibe | Ezetimibe | 93 | 27 |
| Omeprazole | Omeprazole | 88 | 27 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 87 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 84 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 24 |
| Meloxicam | Meloxicam | 82 | 26 |
| Spironolactone | Spironolactone | 79 | 22 |
| Farxiga | Dapagliflozin Propanediol | 77 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 20 |
| Alprazolam | Alprazolam | 73 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 27 |
| Rybelsus | Semaglutide | 65 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 18 |
| Repatha Sureclick | Evolocumab | 62 | suppressed |
| Korlym | Mifepristone | 59 | 12 |
| Verapamil Er | Verapamil Hcl | 58 | 21 |
| Prednisone | Prednisone | 56 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 15 |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 54 | 16 |
| Carvedilol | Carvedilol | 53 | 15 |
| Trulicity | Dulaglutide | 53 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 18 |
| Kerendia | Finerenone | 45 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 45 | 11 |
| Buspirone Hcl | Buspirone Hcl | 44 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Finasteride | Finasteride | 40 | 11 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 19 |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 35 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 21 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 12 |
| Temazepam | Temazepam | 31 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 13 |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 25 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 27 |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Linzess | Linaclotide | 27 | 11 |
| Testosterone | Testosterone | 27 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | 13 |
| Nabumetone | Nabumetone | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Losartan Potassium | Losartan Potassium | 25 | suppressed |
| Tymlos | Abaloparatide | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Famotidine | Famotidine | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 21 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 17 |
| Insulin Lispro | Insulin Lispro | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Victoza 3-Pak | Liraglutide | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Valsartan | Valsartan | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | 11 |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 11 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $869.35 · 50 records | Corcept Therapeutics | AFREZZA, CeQur Simplicity, Cologuard Collection Kit, ENTRESTO, Kerendia, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, Ozempic, POCKET EEG DEVICE, RECORLEV, Rybelsus, XYOSTED, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error